Squarepoint
PYXS icon

Squarepoint’s Pyxis Oncology PYXS Stock Holding History

Squarepoint’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,537
Closed -$25.6K – 4868
2026
Q1 		$25.6K Buy
+17,537
New +$26.4K ﹤0.01% 4172
2025
Q3 		– Sell
-35,428
Closed -$39K – 4867
2025
Q2 		$39K Buy
35,428
+20,514
+138% +$23.1K ﹤0.01% 4340
2025
Q1 		$14.6K Buy
+14,914
New +$19.9K ﹤0.01% 4452
2024
Q2 		– Sell
-68,358
Closed -$291K – 4535
2024
Q1 		$291K Buy
+68,358
New +$287K ﹤0.01% 3411
2023
Q4 		– Sell
-22,556
Closed -$44.9K – 4396
2023
Q3 		$44.9K Buy
+22,556
New +$52.3K ﹤0.01% 3648
2023
Q2 		– Sell
-37,945
Closed -$152K – 3918
2023
Q1 		$152K Buy
+37,945
New +$75.8K ﹤0.01% 2887
2022
Q1 		– Sell
-31,328
Closed -$344K – 3383
2021
Q4 		$344K Buy
+31,328
New +$359K ﹤0.01% 2374

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's PYXS Position: Q2 2026 in Review

Squarepoint sold out of Pyxis Oncology (PYXS) in Q2 2026, closing a stake of 17,537 shares — an estimated $25.6K sold.

Squarepoint first reported a position in PYXS in Q4 2021 and held it in 7 quarters. The position peaked at $344K in Q4 2021. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Squarepoint reported no remaining Pyxis Oncology position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 17,537 Pyxis Oncology shares in Q2 2026, an estimated $25.6K.
  • Squarepoint first reported a position in Pyxis Oncology in Q4 2021 and held it in 7 quarters.
  • Squarepoint's Pyxis Oncology position peaked at $344K in Q4 2021.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.